Angus Chen is a cancer reporter at STAT. He focuses on various aspects of medicine and healthcare, with particular attention to oncology, pancreatic cancer research, and emerging treatments such as immunotherapy and gene therapy. Angus's work has been featured in STAT News, RealClearHealth, RamaOnHealthcare, and The Boston Globe.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Angus Chen's focus on healthcare and pharmaceuticals, particularly around cancer treatment and CAR-T therapy, indicates a preference for data-driven insights. He may be more receptive to pitches that offer access to experts who can provide analysis based on hard scientific evidence or clinical research.
Considering Angus's coverage attributes, he would likely appreciate pitches pertaining to significant events in the healthcare and pharmaceutical industry related to cancer treatment advancements or updates in CAR-T therapy. Pitches with information derived from new studies or findings could also prove beneficial when reaching out to him.
As there is no specific geographic focus mentioned for Angus, it is advisable to tailor relevant topics globally as long as they are pertinent within the context of his coverage themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Matthew Herper, Damian Garde, Angus Chen
Dana-Farber study yielded strong results in 20 patients with smoldering multiple myeloma
By: Matthew Herper, Angus Chen, Damian Garde
You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American Association of Cancer Researchers' annual meeting. Sign up here
By: Angus Chen
Biotech tested daraxonrasib earlier in pancreatic cancer and has preclinical data on a RAS modulator
By: Angus Chen, Damian Garde, Matthew Herper
At AACR, there was talk of Chinese biotech's place in cancer research, oncology’s comms issue, and more.
By: Damian Garde, Angus Chen, Matthew Herper
In the meantime, thanks for joining us. Overcoming resistance and RevMed's next drug?
By: Angus Chen
Telehealth company gets ASCO certification for navigating patient care, supporting in-person clinical team
By: Matthew Herper, Angus Chen, Adam Feuerstein
You're reading the web edition of ASCO in 30 Seconds, STAT's guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions
By: Angus Chen
Protocol could become a third option for high risk, early stage cases
By: Katherine MacPhail, Adam Feuerstein, Matthew Herper, Angus Chen
This is STAT's ASCO in 30 Seconds newsletter You're reading the web edition of ASCO in 30 Seconds, STAT's guide to the American Society of Clinical Oncology annual meeting.
By: Angus Chen, Katherine Macphail, Adam Feuerstein, Matthew Herper
Here is some of what you may have missed from the world's largest cancer research meeting.
